PL44656B1 - - Google Patents
Download PDFInfo
- Publication number
- PL44656B1 PL44656B1 PL44656A PL4465660A PL44656B1 PL 44656 B1 PL44656 B1 PL 44656B1 PL 44656 A PL44656 A PL 44656A PL 4465660 A PL4465660 A PL 4465660A PL 44656 B1 PL44656 B1 PL 44656B1
- Authority
- PL
- Poland
- Prior art keywords
- suppositories
- treatment
- hemorrhoids
- temperature
- prepared
- Prior art date
Links
- 239000000829 suppository Substances 0.000 claims description 8
- 208000014617 hemorrhoid Diseases 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- -1 phthalic acid ester Chemical class 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- QGWDKKHSDXWPET-UHFFFAOYSA-E pentabismuth;oxygen(2-);nonahydroxide;tetranitrate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-2].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O QGWDKKHSDXWPET-UHFFFAOYSA-E 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940100616 topical oil Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Description
Opublikowano dnia 19 czerwca 1061 r. £ a f&ik Sfoz BIBLIOTEKA! Urzedu Pote pilowego POLSKIEJ RZECZYPOSPOLITEJ LUDOWEJ OPIS PATENTOWY Nr 44656 KI. 30 h, 9/06 Waclair Ignacy Chrzaszcz Legionowo, Polska Jerzy Suromiecki Warszawa, Polska Sposób wytwarzania czopków do leczenia hemoroidów Patent trwa od dnia 16 maja 1960 r.Leczenie hemoroidów napotyka na wiele trud¬ nosci ze wzgledu na umiejscowienie i funkcje schorzalego narzadu.Leczenie hemoroidów przeprowadza sie przez miejscowe stosowanie czopków, lub tez na dro¬ dze operacji chirurgicznych.Do sporzadzania czopków do leczenia hemo¬ roidów stosowano oddawna jako podstawe maslo kakaowe, w którym rozpuszczano lub zawiesza¬ no srodki lecznicze jak dermatol, anestezyne, zasadowy azotan bizmutawy lub inne leki. Ma¬ slo kakaowe stosowano równiez w polaczeniu z olejami, woskami, lanolina, jednak dodatki te mialy na celu tylko polepszenie konsystencji i doprowadzenie masy do odpowiedniej tempe¬ ratury topnienia, zblizonej do temperatury ciala ludzkiego.W ostatnich czasach jako podstawa do czop¬ ków uzywane sa polietylenoglikole, utwardzo^ ny olej slonecznikowy, ester kwasu ftalowego z wyzszymi alkoholami tluszczowymi oraz masy syntetyczne.Zaden z wyzej wymienionych srodków uzywa¬ nych jako podstawy do czopków nie posiada dzialania leczniczego na hemoroidy. Przeprowa¬ dzono próby stosowania jako bazy do czopków mieszaniny olbrotu z plynna parafina (The Che¬ mical Formulary, H. Bennett, vel. VI, 1943, str. 70). Poniewaz parafina plynna zwieksza krwa¬ wienia hemoroidów (The Extra Pharmacopoea 1958, str. 1008), masa ta nie znalazla zastosowa¬ nia w lecznictwie. Znane jest równiez doustne stosowanie olbrotu (cetaceum) w postaci table¬ tek w leczeniu hemoroidów, poniewaz jak wy¬ kazaly badania (C A. Howell, The Practitioner, 178, 1957) wywiera on dzialanie lecznicze. Jed¬ nakze stosowanie olbrotu doustnie nie spelnia wszystkich warunków, gdyz wystepuja trudnosci skojarzenia jego dzialania z innymi lekami, któ¬ re w czasie wedrówki przez przewód pokanno-wy ulegaja wchlonieciu, zanim osiagna miejsce schorzale.Trudnosci tych unika sie przy stosowaniu ol- brotu miejscowo w postaci czopków. Jak wyka¬ zaly badania, sam olbrot/stosowany miejscowo dziala niezwykle korzystnie, w polaczeniu zas z innymi lekami uzupelniajacymi uzyskuje sie jeszcze wiekszy efekt terapeutyczny.Sposób wedlug wynalazku polega na stopieniu olbrotu z dodatkiem cieklego nieschnacego oleju roslinnego, ochlodzeniu mieszaniny do tempera¬ tury okolo 40° i shomogenizowaniu z innymi srodkami dzialajacymi leczniczo, np. kwasem ta- ninowym i konserwujacymi np. chlorobutano- lem itd- Z otrzymanej masy wytwarza sie czopki w sposób znany. Dodatek cieklego nieschnacego oleju roslinnego wynosi 1,3 — 1,7 ciezaru olbrotu w zaleznosci od jego temperatury topnienia, któ¬ ra waha sie od 42° do 50°.Przyklad. 30 g olbrotu stopiono na lazni wodnej z 50 g oleju arachidowego i 2 g wosku pszczelego. Po ostudzeniu do temperatury okolo 40° mieszanine shomogenizowano z 13 g kwasu taninowego, dodajac nastepnie chlorobutanol i nipagine A i sporzadzono czopki w znany spo¬ sób. PLPublished on June 19, 1061. £ a f & ik Sfoz LIBRARY! Urzedu Pote Pilowy OF THE POLISH PEOPLE'S REPUBLIC PATENT DESCRIPTION No. 44656 KI. 30 h, 9/06 Waclair Ignacy Chrzaszcz Legionowo, Poland Jerzy Suromiecki Warsaw, Poland Manufacturing of suppositories for the treatment of haemorrhoids The patent has been in force since May 16, 1960 Treatment of haemorrhoids is very difficult due to the location and functions of the diseased organ. For the preparation of suppositories for the treatment of hemorrhoids, cocoa butter has been used for a long time as a base in which medicinal agents such as dermatol, anesthesin, basic bismuth nitrate or other medications. Cocoa butter was also used in conjunction with oils, waxes, lanolin, but these additives were only intended to improve the consistency and bring the mass to an appropriate melting point, close to the temperature of the human body. In recent times, as a basis for suppositories used There are polyethylene glycols, hardened sunflower oil, phthalic acid ester with higher fatty alcohols, and synthetic masses. None of the above-mentioned suppository bases has a curative effect on hemorrhoids. Attempts have been made to use a mixture of oil and liquid paraffin as a suppository base (The Chemical Formulary, H. Bennett, aka VI, 1943, p. 70). Since liquid paraffin increases the bleeding of hemorrhoids (The Extra Pharmacopoea 1958, p. 1008), this mass has not found any therapeutic use. Oral use of cetaceum in the form of tablets in the treatment of hemorrhoids is known because, as studies have shown (C. A. Howell, The Practitioner, 178, 1957), it exerts a therapeutic effect. However, the use of oral gargle does not meet all conditions, as there are difficulties in combining its action with other drugs, which during the journey through the gastrointestinal tract are absorbed before reaching the site of disease. These difficulties are avoided when using gargle locally. in the form of suppositories. As the research has shown, the topical oil itself is extremely beneficial, while in combination with other supplementary drugs, an even greater therapeutic effect is obtained. The method according to the invention consists in melting the olive with the addition of liquid non-drying vegetable oil, cooling the mixture to a temperature of approx. 40 ° and homogenization with other therapeutic agents, for example, tartaric acid and preservatives, for example, chlorobutanol, etc. Suppositories are prepared in a manner known per se. The addition of a liquid non-drying vegetable oil amounts to 1.3-1.7 times the weight of an almond tree depending on its melting point, which varies from 42 ° to 50 °. Example. 30 g of sperm is melted in a water bath with 50 g of peanut oil and 2 g of beeswax. After cooling to a temperature of about 40 °, the mixture was homogenized with 13 g of tannic acid, then chlorobutanol and nipagine A were added, and suppositories were prepared in the usual manner. PL
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL44656B1 true PL44656B1 (en) | 1961-06-15 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT697866E (en) | HIGH DOSE FORMULATIONS | |
| PL44656B1 (en) | ||
| Brobyn | Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis | |
| Guy et al. | Sex hormone sensitization (corpus luteum) | |
| US20170333446A1 (en) | Compounded formula for menopause relief | |
| ES2288133B1 (en) | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS. | |
| DE2951142C2 (en) | Suppository preparation of indomethacin or acemetacin | |
| JP6850883B2 (en) | Use of methyl 4- [9- (6-aminoprynyl)]-2 (S) -hydroxybutyrate for the manufacture of therapeutic agents for psoriasis and vitiligo vulgaris. | |
| RU2129423C1 (en) | Ointment for treating burns and infected injuries | |
| RU2249449C2 (en) | Gynecological egg-shaped vaginal suppositories with dibunol for treating patients for inflammatory diseases | |
| GB2068223A (en) | Antiseptic ointment | |
| DE2058226A1 (en) | Compsn for treating skin infections | |
| JPS60224615A (en) | Medicine composition | |
| JP2022531154A (en) | Compounds and their use for treating autoimmune skin diseases caused by inflammation | |
| DE667500C (en) | Process for the production of base materials for medicinal substances to be introduced into body cavities | |
| JP6484251B2 (en) | Composition comprising bee product | |
| GB455732A (en) | Improvements in or relating to the manufacture of bases for suppositories | |
| Yasmeen | MALAHARA KALPANA: A REVIEW ARTICLE | |
| Oulali | Biopharmaceutical studies of the influence of pharmaceutical factors on the quality indicators of extemporaneouse suppositories | |
| Frank et al. | Oral contraception started early in the puerperium: A clinical study | |
| JPS60188316A (en) | Anti-inflammatory for oral cavity | |
| Romer | Stevens—Johnson Syndrome | |
| PILLSBURY et al. | Intradermal steroid therapy: Hemorrhagic lichen sclerosus et atrophicus | |
| RU2249448C2 (en) | Suppositories with dibunol and oil extraction of propolis for treating patients for gynecological inflammatory diseases | |
| RU2102065C1 (en) | Veterinary composition to prevent and treat postnatal endometritis in cows |